Drug Regulation

FDA Quality Control FDA Approval Controlled Substances DEA Prescription Painkillers Synthetic Opioids FDA Approval Process FDA Operations FDA Oversight

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

The company is targeting an FDA IND in 2027 contingent on supportive preclinical data.